R&D What’s next for oncology research? Eliminating cancer as a cause of death is a highly ambitious goal, but oncology researchers are showing no signs of giving up the fight in 2023.
R&D Plotting the way forward on clinical trial diversity As the old adage goes, the first step towards solving a problem is admitting you have one.
R&D Into the bowels of gut research For people living with Inflammatory Bowel Disease (IBD), navigating life around the risk of flare-ups can be a messy and exhausting challenge.
R&D 12 Questions with Dr Michelle Longmire As the co-founder and chief executive officer of Medable, Dr Michelle Longmire is mission-driven to accelerate the development of new therapies for disease.
R&D Inside out – the coming of age of organ-on-a-chip technology Perhaps the most beautiful thing about pharmacology, and the healthcare industry at large, is the continued pursuit of new ideas and innovations.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.